International Drugmakers Increase Investments in Chinese Biotech Firms for Innovation and Value
Global pharmaceutical companies are intensifying investments in China's biotech sector, attracted by significant room for valuation growth, according to speakers at the Global Health Summit in Hong Kong. Xu Chenming of Citic Securities noted that multinationals are shifting from asset-heavy operations toward investing in Chinese biotech firms. The trend reflects a strategic pivot to tap local innovation.
At the Hong Kong summit, Citic Securities' healthcare lead highlighted a strategic pivot by global drugmakers away from owning heavy physical assets. Instead, they are pursuing equity stakes and partnerships with domestic innovators to leverage local research and development.
Concrete examples include AstraZeneca's recent joint venture with CSPC, where the British firm holds a 49% stake to build a manufacturing hub in Hebei. Similarly, Mölnlycke partnered with Zhende Medical in May, aiming to merge product lines and jointly develop new offerings.
This investment trend could accelerate the maturation of China's domestic biotech ecosystem, potentially giving local firms the capital and global distribution channels needed to scale. For patients worldwide, it may lead to a broader pipeline of affordable, innovative therapies. However, it could also raise concerns about data sovereignty and competitive dynamics, as foreign capital increasingly shapes the strategic direction of national health champions.